|

COCONUT Study Concomitant PVI and LAAC

RECRUITINGSponsored by Asklepios proresearch
Actively Recruiting
SponsorAsklepios proresearch
Started2025-03-01
Est. completion2026-01-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06861673

Summary

In patients with non-valvular AF, at high stroke risk, and who are ineligible for long-term oral anticoagulation LAAC could be an alternative to anticoagulation and safety and efficacy has been shown in several studies and registries.8 While PVI and LAAC are both conducted in the left atrium and share the same access route, a combined concomitant approach might be beneficial for patients but is not conventionally practiced. Due to significantly shorter procedures times and high safety profile PFA based catheter ablation may be advantageous for the combined approach of PVI and LAAC. We are performing a word-wide, retrospective, multicenter registry study focusing on patients with concomitant Farapulse PFA based PVI and LAAC (WATCHMAN Flx, Boston Scientific). To evaluate safety, efficacy and efficiency in a multicenter study the COCONUT study was conducted.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

Indicatio for PVI and LAAC

Exclusion Criteria:

Not eligible for any of the procedures PVI and LAAC

Conditions2

Atrial Fibrillation (AF)Heart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.